From a clinical and scientific point of view METABO intends to contribute in increasing the understanding of the cause-effect relations on metabolic process of lifestyle habits, pharmacological treatments, personal health status and behaviours, to provide more precise information to clinicians and researchers in the pharmaceutical field and to improve the tuning of therapeutic strategies for specific categories of diabetic individuals.
From a social point of view METABO aims to implement the paradigm of integrated patient-cantered care creating a virtual circle between patients, caring physicians and healthcare provider organisations, and also empowering individuals to directly control and manage their disease, so shifting from a physician-driven care to a patient-managed self monitoring and care.
From a business perspective METABO middleware solution is a prospect interesting product for producers of medical devices and sensors, who could offer additional monitoring facilities to their customers (hospitals, patients). The research and validation performed during METABO will also provide additional knowledge and results usable for enhancing monitoring products and equipment so adding to their competitive advantage on the specific market. The METABO platform integrates models and care pathways generators and can constitute a valuable tool for hospitals and health networks (regional or local) linking general practitioners, reference hospitals and territory surgeries. On the other hand the modular architecture of METABO platform enables an easy and low-cost adaptation to other medical domains, so offering a market opportunity for IT providers active in the healthcare sector.
From a technological point of view METABO will integrate the latest achievements in the domain of on-body and environmental monitoring through a single middleware using REpresentational State Transfer (REST) Architecture. The Platform will be enriched with a suite of tools for:
© Copyright 2008 Metabo Project.
All rights reserved.
METABO project is partially funded by the European Commission.